

---

## Lifco Q2 2025 - Short-term pain

Redeye nudges down its estimates and valuation following Lifco's Q2 2025 report. While margins aligned with our projections, sales and EBITA missed our forecasts. Organic softness in business area Systems Solutions and FX headwinds weighed on Q2 figures, and we expect these factors to persist in the short term. We expect Lifco's solid M&A momentum to continue in H2 2025e.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Lifco Q2 2025 - Short-term pain**